Canada - English - Health Canada

ivax pharmaceuticals incorporated - salbutamol (salbutamol sulfate) - solution - 1mg - salbutamol (salbutamol sulfate) 1mg - selective beta 2-adrenergic agonists

Canada - English - Health Canada

teva canada limited - salbutamol (salbutamol sulfate); ipratropium bromide (ipratropium bromide monohydrate) - solution - 2.5mg; 0.5mg - salbutamol (salbutamol sulfate) 2.5mg; ipratropium bromide (ipratropium bromide monohydrate) 0.5mg - antimuscarinics antispasmodics

Canada - English - Health Canada

teva canada limited - salbutamol (salbutamol sulfate) - metered-dose aerosol - 100mcg - salbutamol (salbutamol sulfate) 100mcg - selective beta 2-adrenergic agonists

Canada - English - Health Canada

sanis health inc - salbutamol (salbutamol sulfate) - metered-dose aerosol - 100mcg - salbutamol (salbutamol sulfate) 100mcg - selective beta 2-adrenergic agonists

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - salbutamol sulfate, quantity: 0.6 mg/ml (equivalent: salbutamol, qty 0.5 mg/ml) - injection, solution - excipient ingredients: sodium chloride; sulfuric acid; water for injections - indications as at 3rd december 2002: for the relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise-induced asthma or in other situations known to induce bronchospasm.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - atenolol, quantity: 50 mg - tablet, film coated - excipient ingredients: sodium lauryl sulfate; pregelatinised maize starch; hypromellose; colloidal anhydrous silica; magnesium stearate; sodium starch glycollate; microcrystalline cellulose; titanium dioxide; indigo carmine; methylcellulose; macrogol 400 - atenolol is indicated in the management of: 1. all grades of hypertension, including hypertension of renal origin. 2. frequent disabling angina without evidence of cardiac failure. 3. cardiac arrhythmias (maintenance treatment of supraventricular and ventricular arrhythmiaswhich have been controlled with intravenous atenol, including those associated with acute myocardial infarction). 4. myocardial infarction: late intervention (beta-blocker class effect).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - atenolol, quantity: 50 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; hypromellose; sodium starch glycollate; colloidal anhydrous silica; microcrystalline cellulose; sodium lauryl sulfate; magnesium stearate; titanium dioxide; indigo carmine; methylcellulose; macrogol 400 - atenolol is indicated in the management of: 1. all grades of hypertension, including hypertension of renal origin. 2. frequent disabling angina without evidence of cardiac failure. 3. cardiac arrhythmias (maintenance treatment of supraventricular and ventricular arrhythmias, including those associated with acute myocardial infarction). 4. myocardial infarction: late intervention (beta-blocker class effect greater than 12 hours after onset of chest pain).

Namibia - English - Namibia Medicines Regulatory Council

adcock ingram limited - bromhexine hydrochloride, orciprenaline sulphate - syrup - each 5 ml syrup contains: bromhexine hydrochloride 4,0 mg, orciprenaline sulphate 5,0 mg

Namibia - English - Namibia Medicines Regulatory Council

johnson & johnson medical (pty) ltd - bromhexine hydrochloride, orciprenaline sulphate - syrup - each 5 ml liquid contains bromhexine hydrochloride 4 mg, orciprenaline sulphate 5 mg

Namibia - English - Namibia Medicines Regulatory Council

johnson & johnson medical (pty) ltd - bromhexine hydrochloride, orciprenaline sulphate - syrup - each 5 ml contains; bromhexine hydrochloride 4 mg, orciprenaline sulphate 5 mg